Any feedback?
Information on EC 1.1.1.141 - 15-hydroxyprostaglandin dehydrogenase (NAD+)
for references in articles please use BRENDA:EC1.1.1.141Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
1.1.1.141 15-hydroxyprostaglandin dehydrogenase (NAD+)IUBMB Comments
Acts on prostaglandin E2, F2alpha and B1, but not on prostaglandin D2. cf. EC 1.1.1.196 15-hydroxyprostaglandin-D dehydrogenase (NADP+) and EC 1.1.1.197 15-hydroxyprostaglandin dehydrogenase (NADP+).
Specify your search results
Word Map
- 1.1.1.141
- cox-2
- cyclooxygenase-2
- fetal
-
arachidonic
- pregnancy
- chorion
- labor
-
pgf2alpha
- indomethacin
-
parturition
-
nsaid
- trophoblast
-
preterm
- myometrium
-
chemoprevention
-
15-keto
-
eicosanoids
-
thromboxane
-
prostanoids
- decidua
- synthase-1
-
nadp-linked
-
15-keto-pge2
-
clubbing
-
cesarean
- osteoarthropathy
- prostacyclin
- amnion
-
beta-hydroxysteroid
-
lipoxins
- calcitriol
-
9-ketoreductase
- medicine
-
slco2a1
-
6-keto-pgf1
- drug development
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria
Reaction Schemes
Synonyms
15-pgdh, 15-hydroxyprostaglandin dehydrogenase, prostaglandin dehydrogenase, 15-prostaglandin dehydrogenase, 15-hydroxy prostaglandin dehydrogenase, nad+-dependent 15-hydroxyprostaglandin dehydrogenase, 15-oh-pgdh, nad-dependent 15-hydroxyprostaglandin dehydrogenase, nad+-linked 15-hydroxyprostaglandin dehydrogenase, 15-hydroxyprostaglandin-dehydrogenase, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
11alpha,15-dihydroxy-9-oxoprost-13-enoate:NAD+ 15-oxidoreductase
-
-
-
-
15-hydroxyprostanoic dehydrogenase
-
-
-
-
15-OH-PGDH
-
-
-
-
dehydrogenase, 15-hydroxyprostaglandin
-
-
-
-
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (type I)
-
-
-
-
NAD-specific 15-hydroxyprostaglandin dehydrogenase
-
-
-
-
PGDH
-
-
-
-
prostaglandin dehydrogenase
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
redox reaction
-
-
-
-
oxidation
-
-
-
-
reduction
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate:NAD+ 15-oxidoreductase
Acts on prostaglandin E2, F2alpha and B1, but not on prostaglandin D2. cf. EC 1.1.1.196 15-hydroxyprostaglandin-D dehydrogenase (NADP+) and EC 1.1.1.197 15-hydroxyprostaglandin dehydrogenase (NADP+).
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
9030-87-9
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
?
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
i.e. 15-hydroxyprostaglandin or (15S)-PGE2
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+
(5Z,13E)-11alpha-hydroxy-9,15-dioxoprost-5,13-dienoate + NADH + H+
-
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
COFACTOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Aberrant Crypt Foci
15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis.
Aberrant Crypt Foci
Concerted actions of ameliorated colitis, aberrant crypt foci inhibition and 15-hydroxyprostaglandin dehydrogenase induction by sonic hedgehog inhibitor led to prevention of colitis-associated cancer.
Abortion, Spontaneous
Early pregnancy loss in 15-hydroxyprostaglandin dehydrogenase knockout (15-HPGD-/-) mice due to requirement for embryo 15-HPGD activity.
Acromegaly
Treatment of acromegaly by rosiglitazone via upregulating 15-PGDH in both pituitary adenoma and liver.
Acute Kidney Injury
15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury.
Acute Kidney Injury
Pharmacologic Blockade of 15-PGDH Protects Against Acute Renal Injury Induced by LPS in Mice.
Adenocarcinoma
11-Oxoeicosatetraenoic acid is a cyclooxygenase-2/15-hydroxyprostaglandin dehydrogenase-derived antiproliferative eicosanoid.
Adenocarcinoma
15-Hydroxyprostaglandin dehydrogenase as a marker in colon carcinogenesis: analysis of the prostaglandin pathway in human colonic tissue.
Adenocarcinoma
Correlation of 15-prostagladin dehydrogenase expression with clinicopathological factors and survival rate in gastric adenocarcinoma.
Adenocarcinoma
Inhibition of 15-PGDH causes Kras-driven tumor expansion through prostaglandin E2-ALDH1 signaling in the pancreas.
Adenocarcinoma
MicroRNA-21 induces loss of 15-hydroxyprostaglandin dehydrogenase in early gastric tubular adenocarcinoma.
Adenocarcinoma
Reduction of 15-hydroxyprostaglandin dehydrogenase expression is an independent predictor of poor survival associated with enhanced cell proliferation in gastric adenocarcinoma.
Adenocarcinoma
Relationship between 15-hydroxyprostaglandin dehydrogenase and gastric adenocarcinoma.
Adenocarcinoma of Lung
15-Hydroxyprostaglandin dehydrogenase can be induced by dexamethasone and other glucocorticoids at the therapeutic level in A549 human lung adenocarcinoma cells.
Adenocarcinoma of Lung
Histone deacetylase inhibitors and transforming growth factor-beta induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells.
Adenocarcinoma of Lung
Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells.
Adenoma
15-Hydroxyprostaglandin dehydrogenase as a marker in colon carcinogenesis: analysis of the prostaglandin pathway in human colonic tissue.
Adenoma
15-hydroxyprostaglandin dehydrogenase in colorectal mucosa as a potential biomarker for predicting colorectal neoplasms.
Adenoma
15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors.
Adenoma
15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis.
Adenoma
?-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells.
Adenoma
Chemopreventive Efficacy of the Cyclooxygenase-2 (Cox-2) Inhibitor, Celecoxib, Is Predicted by Adenoma Expression of Cox-2 and 15-PGDH.
Adenoma
Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma.
Adenoma
Loss of 15-hydroxyprostaglandin dehydrogenase indicates a tumor suppressor role in pituitary adenomas.
Adenoma
Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer.
Adenoma
Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.
Adenomatous Polyposis Coli
15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis.
Amyotrophic Lateral Sclerosis
Increased Expression of 15-Hydroxyprostaglandin Dehydrogenase in Spinal Astrocytes During Disease Progression in a Model of Amyotrophic Lateral Sclerosis.
Anaphylaxis
PGE2 deficiency predisposes to anaphylaxis by causing mast cell hyperresponsiveness.
Aortic Aneurysm, Abdominal
Expression and Cellular Localization of 15-Hydroxy-Prostaglandin-Dehydrogenase in Abdominal Aortic Aneurysm.
Arthritis
Limited effect of anti-rheumatic treatment on 15-prostaglandin dehydrogenase in rheumatoid arthritis synovial tissue.
Arthritis, Rheumatoid
15-hydroxyprostaglandin dehydrogenase is upregulated by hydroxychloroquine in rheumatoid arthritis fibroblast-like synoviocytes.
Arthritis, Rheumatoid
Limited effect of anti-rheumatic treatment on 15-prostaglandin dehydrogenase in rheumatoid arthritis synovial tissue.
Bone Marrow Failure Disorders
Inhibition of 15-PGDH Protects Mice from Immune-Mediated Bone Marrow Failure.
Breast Neoplasms
15-Deoxy-?12,14-prostaglandin J2 induces expression of 15-hydroxyprostaglandin dehydrogenase through Elk-1 activation in human breast cancer MDA-MB-231 cells.
Breast Neoplasms
15-Deoxy-?12,14-prostaglandin J2 upregulates the expression of 15-hydroxyprostaglandin dehydrogenase through DNA methyltransferase 1 inactivation.
Breast Neoplasms
15-Hydroxyprostaglandin dehydrogenase associates with poor prognosis in breast cancer, induces epithelial-mesenchymal transition, and promotes cell migration in cultured breast cancer cells.
Breast Neoplasms
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer.
Breast Neoplasms
15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma.
Breast Neoplasms
Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer.
Breast Neoplasms
Cigarette Smoke Regulates Calcium-Independent Phospholipase A2 Metabolic Pathways in Breast Cancer.
Breast Neoplasms
Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ER?-positive breast cancer.
Breast Neoplasms
Lipoxygenase catalyzed metabolites derived from docosahexaenoic acid are promising antitumor agents against breast cancer.
Breast Neoplasms
Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer.
Breast Neoplasms
Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer.
Breast Neoplasms
Non-canonical WNT5A signaling up-regulates the expression of the tumor suppressor 15-PGDH and induces differentiation of colon cancer cells.
Breast Neoplasms
Oncolytic herpes simplex virus 1 encoding 15-prostaglandin dehydrogenase mitigates immune suppression and reduces ectopic primary and metastatic breast cancer in mice.
Breast Neoplasms
Prostaglandin metabolising enzymes and PGE2 are inversely correlated with vitamin D receptor and 25(OH)2D3 in breast cancer.
Breast Neoplasms
Thiamine transporter gene expression and exogenous thiamine modulate the expression of genes involved in drug and prostaglandin metabolism in breast cancer cells.
Breast Neoplasms
Upregulation of Cyclooxygenase-2/Prostaglandin E2 (COX-2/PGE2) Pathway Member Multiple Drug Resistance-Associated Protein 4 (MRP4) and Downregulation of Prostaglandin Transporter (PGT) and 15-Prostaglandin Dehydrogenase (15-PGDH) in Triple-Negative Breast Cancer.
Carcinogenesis
15-Hydroxyprostaglandin dehydrogenase as a marker in colon carcinogenesis: analysis of the prostaglandin pathway in human colonic tissue.
Carcinogenesis
15-Hydroxyprostaglandin dehydrogenase as a novel molecular target for cancer chemoprevention and therapy.
Carcinogenesis
15-hydroxyprostaglandin dehydrogenase in colorectal mucosa as a potential biomarker for predicting colorectal neoplasms.
Carcinogenesis
15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer.
Carcinogenesis
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human gastric cancer.
Carcinogenesis
15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis.
Carcinogenesis
15-Hydroxyprostaglandin dehydrogenase suppresses K-RasV12-dependent tumor formation in Nu/Nu mice.
Carcinogenesis
15-PGDH Expression in Gastric Cancer: A Potential Role in Anti-Tumor Immunity.
Carcinogenesis
5-aminosalicylic acid mediates expression of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase to suppress colorectal tumorigenesis.
Carcinogenesis
?-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells.
Carcinogenesis
Bile acids inhibit NAD+-dependent 15-hydroxyprostaglandin dehydrogenase transcription in colonocytes.
Carcinogenesis
Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells.
Carcinogenesis
Correlation of 15-prostagladin dehydrogenase expression with clinicopathological factors and survival rate in gastric adenocarcinoma.
Carcinogenesis
Curcumin induces expression of 15-hydroxyprostaglandin dehydrogenase in gastric mucosal cells and mouse stomach in vivo: AP-1 as a potential target.
Carcinogenesis
Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer.
Carcinogenesis
Inflammation Modulation by Vitamin D and Calcium in the Morphologically Normal Colorectal Mucosa of Colorectal Adenoma Patients in a Clinical Trial.
Carcinogenesis
Inhibition of 15-Hydroxyprostaglandin Dehydrogenase by Helicobacter pylori in Human Gastric Carcinogenesis.
Carcinogenesis
MicroRNA-21 induces loss of 15-hydroxyprostaglandin dehydrogenase in early gastric tubular adenocarcinoma.
Carcinogenesis
miR-21 modulates prostaglandin signaling and promotes gastric tumorigenesis by targeting 15-PGDH.
Carcinogenesis
NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer.
Carcinogenesis
Nuclear Factor Erythroid 2-related Factor 2 Knockout Suppresses the Development of Aggressive Colorectal Cancer Formation Induced by Azoxymethane/Dextran Sulfate Sodium-Treatment in Female Mice.
Carcinogenesis
Suppression of invasive properties of colorectal carcinoma SW480 cells by 15-hydroxyprostaglandin dehydrogenase gene.
Carcinogenesis
Synthetic triterpenoid induces 15-PGDH expression and suppresses inflammation-driven colon carcinogenesis.
Carcinogenesis
The ?-3 polyunsaturated fatty acids prevented colitis-associated carcinogenesis through blocking dissociation of ?-catenin complex, inhibiting COX-2 through repressing NF-?B, and inducing 15-prostaglandin dehydrogenase.
Carcinogenesis
The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment.
Carcinoma
15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis.
Carcinoma
15-PGDH is reduced and induces apoptosis and cell cycle arrest in gastric carcinoma.
Carcinoma
?-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells.
Carcinoma
Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer.
Carcinoma
Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.
Carcinoma
Decreased expression of 15-hydroxyprostaglandin dehydrogenase in gastric carcinomas.
Carcinoma
Effect of 15-hydroxyprostaglandin dehydrogenase gene on the proliferation of gastric cancer cell murine forestomach carcinoma.
Carcinoma
Experimental cancer therapy using restoration of NAD+ -linked 15-hydroxyprostaglandin dehydrogenase expression.
Carcinoma
Expression of 15-hydroxyprostaglandin dehydrogenase, a COX-2 antagonist and tumour suppressor, is not altered in gastric carcinomas.
Carcinoma
Expression of vitamin D receptor (VDR), cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25(OH(2))D(3)) and prostaglandin E(2) (PGE(2)) serum level in ovarian cancer patients.
Carcinoma
MicroRNA-21 regulates prostaglandin E2 signaling pathway by targeting 15-hydroxyprostaglandin dehydrogenase in tongue squamous cell carcinoma.
Carcinoma
Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia.
Carcinoma, Hepatocellular
15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE2/PPAR?-mediated activation of p21(WAF1/Cip1.)
Carcinoma, Hepatocellular
Regulation of 15-hydroxyprostaglandin dehydrogenase expression in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Role of 15-hydroxyprostaglandin dehydrogenase down-regulation on the prognosis of hepatocellular carcinoma.
Carcinoma, Non-Small-Cell Lung
Expression of 15-hydroxyprostaglandin dehydrogenase and cyclooxygenase-2 in non-small cell lung cancer: Correlations with angiogenesis and prognosis.
Carcinoma, Non-Small-Cell Lung
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer.
Carcinoma, Squamous Cell
MicroRNA-21 regulates prostaglandin E2 signaling pathway by targeting 15-hydroxyprostaglandin dehydrogenase in tongue squamous cell carcinoma.
Cholangiocarcinoma
?-3 polyunsaturated fatty acids upregulate 15-PGDH expression in cholangiocarcinoma cells by inhibiting miR-26a/b expression.
Cholangiocarcinoma
Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids.
Chordoma
Aberrant Expression of Extracellular Signal-Regulated Kinase and 15-Hydroxyprostaglandin Dehydrogenase Indicates Radiation Resistance and Poor Prognosis for Patients with Clival Chordomas.
Choriocarcinoma
Nicotinamide adenine dinucleotide-dependent 15-hydroxyprostaglandin dehydrogenase activity in hydatidiform mole tissue and choriocarcinoma cells.
Colitis
Concerted actions of ameliorated colitis, aberrant crypt foci inhibition and 15-hydroxyprostaglandin dehydrogenase induction by sonic hedgehog inhibitor led to prevention of colitis-associated cancer.
Colitis
Damage control: Harnessing prostaglandin E2 as a potential healing factor of tissue injuries.
Colitis
Resolution of Cox mediated inflammation by Se supplementation in mouse experimental model of colitis.
Colitis, Ulcerative
Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.
Colitis, Ulcerative
Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha.
Colitis-Associated Neoplasms
Concerted actions of ameliorated colitis, aberrant crypt foci inhibition and 15-hydroxyprostaglandin dehydrogenase induction by sonic hedgehog inhibitor led to prevention of colitis-associated cancer.
Colitis-Associated Neoplasms
Sonic hedgehog inhibitors prevent colitis-associated cancer via orchestrated mechanisms of IL-6/gp130 inhibition, 15-PGDH induction, Bcl-2 abrogation, and tumorsphere inhibition.
Colitis-Associated Neoplasms
Synthetic triterpenoid induces 15-PGDH expression and suppresses inflammation-driven colon carcinogenesis.
Colonic Neoplasms
15-Deoxy-?12,14-prostaglandin J2 Upregulates the Expression of 15-Hydroxyprostaglandin Dehydrogenase by Inducing AP-1 Activation and Heme Oxygenase-1 Expression in Human Colon Cancer Cells.
Colonic Neoplasms
15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells.
Colonic Neoplasms
15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer.
Colonic Neoplasms
15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis.
Colonic Neoplasms
15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.
Colonic Neoplasms
15-Keto prostaglandin E2 induces heme oxygenase-1 expression through activation of Nrf2 in human colon epithelial CCD 841 CoN cells.
Colonic Neoplasms
15-PGDH regulated PD-1/PD-L1 immune checkpoint blockade immunotherapy in colon cancer is a TNF-? dependent phenomenon.
Colonic Neoplasms
A potential anti-tumor effect of leukotriene C4 through the induction of 15-hydroxyprostaglandin dehydrogenase expression in colon cancer cells.
Colonic Neoplasms
Anti-angiogenic action of leukotriene-C4 induced 15-hydroxyprostaglandin dehydrogenase in colon cancer cells is a TNF-? dependent phenomenon.
Colonic Neoplasms
Anti-cancer Effects of MW-03, a Novel Indole Compound, by Inducing 15-Hydroxyprostaglandin Dehydrogenase and Cellular Growth Inhibition in the LS174T Human Colon Cancer Cell Line.
Colonic Neoplasms
Bile acids inhibit NAD+-dependent 15-hydroxyprostaglandin dehydrogenase transcription in colonocytes.
Colonic Neoplasms
Erratum: 15-Deoxy-?12,14-prostaglandin J2 Upregulates the Expression of 15-Hydroxyprostaglandin Dehydrogenase by Inducing AP-1 Activation and Heme Oxygenase-1 Expression in Human Colon Cancer Cells.
Colonic Neoplasms
Genetic variation in 15-hydroxyprostaglandin dehydrogenase and colon cancer susceptibility.
Colonic Neoplasms
miR-21-mediated regulation of 15-hydroxyprostaglandin dehydrogenase in colon cancer.
Colonic Neoplasms
Non-canonical WNT5A signaling up-regulates the expression of the tumor suppressor 15-PGDH and induces differentiation of colon cancer cells.
Colonic Neoplasms
Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs).
Colonic Neoplasms
Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer.
Colonic Neoplasms
Single nucleotide polymorphism rs2555639 in 15-PGDH and colorectal cancer metastasis.
Colonic Neoplasms
Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.
Colonic Neoplasms
Suppression of invasive properties of colorectal carcinoma SW480 cells by 15-hydroxyprostaglandin dehydrogenase gene.
Colonic Neoplasms
Tumour suppressor 15-hydroxyprostaglandin dehydrogenase induces differentiation in colon cancer via GLI1 inhibition.
Colonic Neoplasms
Tumour-suppressive effect of oestrogen receptor ? in colorectal cancer patients, colon cancer cells, and a zebrafish model.
Colorectal Neoplasms
15-hydroxyprostaglandin dehydrogenase in colorectal mucosa as a potential biomarker for predicting colorectal neoplasms.
Colorectal Neoplasms
15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer.
Colorectal Neoplasms
15-Hydroxyprostaglandin dehydrogenase suppresses K-RasV12-dependent tumor formation in Nu/Nu mice.
Colorectal Neoplasms
5-aminosalicylic acid mediates expression of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase to suppress colorectal tumorigenesis.
Colorectal Neoplasms
?-catenin negatively regulates expression of the prostaglandin transporter PGT in the normal intestinal epithelium and colorectal tumour cells: a role in the chemopreventive efficacy of aspirin?
Colorectal Neoplasms
?-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells.
Colorectal Neoplasms
Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD).
Colorectal Neoplasms
Colon tumour cells increase PGE(2) by regulating COX-2 and 15-PGDH to promote survival during the microenvironmental stress of glucose deprivation.
Colorectal Neoplasms
Effect of ginger root on cyclooxygenase-1 and 15-hydroxyprostaglandin dehydrogenase expression in colonic mucosa of humans at normal and increased risk for colorectal cancer.
Colorectal Neoplasms
HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells.
Colorectal Neoplasms
HSP90 Inhibition Suppresses PGE2 Production via Modulating COX-2 and 15-PGDH Expression in HT-29 Colorectal Cancer Cells.
Colorectal Neoplasms
Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer.
Colorectal Neoplasms
Non-canonical WNT5A signaling up-regulates the expression of the tumor suppressor 15-PGDH and induces differentiation of colon cancer cells.
Colorectal Neoplasms
Prognostic implication of 15-hydroxyprostaglandin dehydrogenase down-regulation in patients with colorectal cancer.
Colorectal Neoplasms
Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer.
Colorectal Neoplasms
Single nucleotide polymorphism rs2555639 in 15-PGDH and colorectal cancer metastasis.
Colorectal Neoplasms
Suppression of invasive properties of colorectal carcinoma SW480 cells by 15-hydroxyprostaglandin dehydrogenase gene.
Colorectal Neoplasms
Tumour suppressor 15-hydroxyprostaglandin dehydrogenase induces differentiation in colon cancer via GLI1 inhibition.
Coronary Stenosis
Prostaglandin E2 (PGE2) synthesis pathway is involved in coronary artery stenosis and restenosis.
Crohn Disease
Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha.
Cysts
Apocrine cysts of the breast: biomarkers, origin, enlargement, and relation with cancer phenotype.
Ductus Arteriosus, Patent
Effect of dexamethasone on fetal lung 15-hydroxy-prostaglandin dehydrogenase: possible mechanism for the prevention of patent ductus arteriosus by maternal dexamethasone therapy.
Endometriosis
Expression of eicosanoid biosynthetic and catabolic enzymes in peritoneal endometriosis.
Esophageal Neoplasms
Expression of PGDH Correlates with Cell Growth in Both Esophageal Squamous Cell Carcinoma and Adenocarcinoma.
Gastritis
15-Hydroxyprostaglandin Dehydrogenase is Downregulated and Exhibits Tumor Suppressor Activity in Gastric Cancer.
Gastrointestinal Neoplasms
15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.
Gastrointestinal Neoplasms
Inhibition of 15-Hydroxyprostaglandin Dehydrogenase by Helicobacter pylori in Human Gastric Carcinogenesis.
Glioblastoma
Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase.
Glioblastoma
Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs).
Glioma
Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase.
Herpes Simplex
Oncolytic herpes simplex virus 1 encoding 15-prostaglandin dehydrogenase mitigates immune suppression and reduces ectopic primary and metastatic breast cancer in mice.
Hydatidiform Mole
Nicotinamide adenine dinucleotide-dependent 15-hydroxyprostaglandin dehydrogenase activity in hydatidiform mole tissue and choriocarcinoma cells.
Hypertension
Kidney 15-hydroxy-prostaglandin-dehydrogenase activity during the development of experimental hypertension in the rat.
Hypertension
Renal prostaglandin excretion and metabolism in male and female New Zealand normotensive and genetically hypertensive rats.
Hypertension, Pulmonary
15-PGDH/15-KETE plays a role in hypoxia-induced pulmonary vascular remodeling through ERK1/2-dependent PAR-2 pathway.
Hyperthyroidism
Experimental hyperthyroidism in rats suppresses in vitro prostaglandin metabolism in lung and kidney.
Infections
15-hydroxyprostaglandin dehydrogenase: implications in preterm labor with and without ascending infection.
Infections
Immunoreactive 15-hydroxyprostaglandin dehydrogenase (PGDH) is reduced in fetal membranes from patients at preterm delivery in the presence of infection.
Infections
Inhibition of 15-Hydroxyprostaglandin Dehydrogenase by Helicobacter pylori in Human Gastric Carcinogenesis.
Infections
Localization of prostaglandin H synthase, prostaglandin dehydrogenase, corticotropin releasing hormone and glucocorticoid receptor in rhesus monkey fetal membranes with labor and in the presence of infection.
Infections
Oncolytic herpes simplex virus 1 encoding 15-prostaglandin dehydrogenase mitigates immune suppression and reduces ectopic primary and metastatic breast cancer in mice.
Infections
[Spontaneous premature birth: physiopathology, predictors and management. The frequency is constant--early detection can improve therapeutic possibilities]
Inflammatory Bowel Diseases
Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha.
Intestinal Polyposis
Endogenous conversion of ?-6 to ?-3 polyunsaturated fatty acids in fat-1 mice attenuated intestinal polyposis by either inhibiting COX-2/?-catenin signaling or activating 15-PGDH/IL-18.
Intracranial Aneurysm
Differential Sex Response to Aspirin in Decreasing Aneurysm Rupture in Humans and Mice.
Intracranial Aneurysm
Sex Differential in 15-Hydroxyprostaglandin Dehydrogenase Levels in the Lumen of Human Intracranial Aneurysms.
Leukemia
Effect of two antiprogestins (mifepristone and onapristone) on endometrial factors of potential importance for implantation.
Leukemia
Metabolism of cyclooxygenase and lipoxygenase products by 15-prostaglandin dehydrogenase from human HL-60 leukemia cells.
Lung Diseases
Novel keto-phospholipids are generated by monocytes and macrophages, detected in cystic fibrosis, and activate peroxisome proliferator-activated receptor-?.
Lung Neoplasms
15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer.
Lung Neoplasms
Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells.
Lung Neoplasms
Expression of 15-hydroxyprostaglandin dehydrogenase and cyclooxygenase-2 in non-small cell lung cancer: Correlations with angiogenesis and prognosis.
Lung Neoplasms
Focusing downstream in lung cancer prevention: 15-hydroxyprostaglandin dehydrogenase.
Lung Neoplasms
Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer.
Lung Neoplasms
Interleukin-4 up-regulates 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in human lung cancer cells.
Lung Neoplasms
Interleukin-4 UP-regulates 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in human lung cancer cells.
Lung Neoplasms
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer.
Lung Neoplasms
NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer.
Lung Neoplasms
Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase.
Lung Neoplasms
Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs).
Lymphatic Metastasis
15-PGDH expression as a predictive factor response to neoadjuvant chemotherapy in advanced gastric cancer.
Lymphatic Metastasis
15-PGDH Expression in Gastric Cancer: A Potential Role in Anti-Tumor Immunity.
Lymphatic Metastasis
Downregulation of 15-hydroxyprostaglandin dehydrogenase by interleukin-1? from activated macrophages leads to poor prognosis in pancreatic cancer.
Muscular Atrophy
Inhibition of prostaglandin-degrading enzyme 15-PGDH rejuvenates aged muscle mass and strength.
Neoplasm Metastasis
15-PGDH expression as a predictive factor response to neoadjuvant chemotherapy in advanced gastric cancer.
Neoplasm Metastasis
15-PGDH Expression in Gastric Cancer: A Potential Role in Anti-Tumor Immunity.
Neoplasm Metastasis
Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer.
Neoplasm Metastasis
Correlation of 15-prostagladin dehydrogenase expression with clinicopathological factors and survival rate in gastric adenocarcinoma.
Neoplasm Metastasis
Decreased expression of 15-hydroxyprostaglandin dehydrogenase in gastric carcinomas.
Neoplasm Metastasis
Downregulation of 15-hydroxyprostaglandin dehydrogenase by interleukin-1? from activated macrophages leads to poor prognosis in pancreatic cancer.
Neoplasm Metastasis
Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer.
Neoplasm Metastasis
Oncolytic herpes simplex virus 1 encoding 15-prostaglandin dehydrogenase mitigates immune suppression and reduces ectopic primary and metastatic breast cancer in mice.
Neoplasm Metastasis
Regional differences in prostaglandin E2 metabolism in human colorectal cancer liver metastases.
Neoplasm Metastasis
Single nucleotide polymorphism rs2555639 in 15-PGDH and colorectal cancer metastasis.
Neoplasm Metastasis
Suppression of invasive properties of colorectal carcinoma SW480 cells by 15-hydroxyprostaglandin dehydrogenase gene.
Neoplasms
15-Deoxy-?12,14-prostaglandin J2 induces expression of 15-hydroxyprostaglandin dehydrogenase through Elk-1 activation in human breast cancer MDA-MB-231 cells.
Neoplasms
15-Deoxy-?12,14-prostaglandin J2 upregulates the expression of 15-hydroxyprostaglandin dehydrogenase through DNA methyltransferase 1 inactivation.
Neoplasms
15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells.
Neoplasms
15-Hydroxyprostaglandin dehydrogenase as a novel molecular target for cancer chemoprevention and therapy.
Neoplasms
15-hydroxyprostaglandin dehydrogenase in colorectal mucosa as a potential biomarker for predicting colorectal neoplasms.
Neoplasms
15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors.
Neoplasms
15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer.
Neoplasms
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer.
Neoplasms
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human gastric cancer.
Neoplasms
15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis.
Neoplasms
15-Hydroxyprostaglandin Dehydrogenase is Downregulated and Exhibits Tumor Suppressor Activity in Gastric Cancer.
Neoplasms
15-Hydroxyprostaglandin dehydrogenase suppresses K-RasV12-dependent tumor formation in Nu/Nu mice.
Neoplasms
15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.
Neoplasms
15-Keto prostaglandin E2 induces heme oxygenase-1 expression through activation of Nrf2 in human colon epithelial CCD 841 CoN cells.
Neoplasms
15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE2/PPAR?-mediated activation of p21(WAF1/Cip1.)
Neoplasms
?-3 polyunsaturated fatty acids upregulate 15-PGDH expression in cholangiocarcinoma cells by inhibiting miR-26a/b expression.
Neoplasms
?-catenin negatively regulates expression of the prostaglandin transporter PGT in the normal intestinal epithelium and colorectal tumour cells: a role in the chemopreventive efficacy of aspirin?
Neoplasms
?-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells.
Neoplasms
A potential anti-tumor effect of leukotriene C4 through the induction of 15-hydroxyprostaglandin dehydrogenase expression in colon cancer cells.
Neoplasms
Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer.
Neoplasms
Apocrine cysts of the breast: biomarkers, origin, enlargement, and relation with cancer phenotype.
Neoplasms
Apricoxib upregulates 15-PGDH and PGT in tobacco-related epithelial malignancies.
Neoplasms
Breast cancer--new aspects of tumor biology: are calcitriol and cyclooxygenase-2 possible targets for breast cancer?
Neoplasms
Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer.
Neoplasms
Chemopreventive Efficacy of the Cyclooxygenase-2 (Cox-2) Inhibitor, Celecoxib, Is Predicted by Adenoma Expression of Cox-2 and 15-PGDH.
Neoplasms
Colon tumour cells increase PGE(2) by regulating COX-2 and 15-PGDH to promote survival during the microenvironmental stress of glucose deprivation.
Neoplasms
Colonic 15-PGDH Levels Are Stable Across Distance and Time and Are Not Perturbed by Aspirin Intervention.
Neoplasms
Concerted actions of ameliorated colitis, aberrant crypt foci inhibition and 15-hydroxyprostaglandin dehydrogenase induction by sonic hedgehog inhibitor led to prevention of colitis-associated cancer.
Neoplasms
Correlation of 15-prostagladin dehydrogenase expression with clinicopathological factors and survival rate in gastric adenocarcinoma.
Neoplasms
Cyclooxygenase-2 expression is related to the epithelial-to-mesenchymal transition in human colon cancers.
Neoplasms
Decreased expression of 15-hydroxyprostaglandin dehydrogenase in gastric carcinomas.
Neoplasms
Decreased systemic IGF-1 in response to calorie restriction modulates murine tumor cell growth, nuclear factor-?B activation, and inflammation-related gene expression.
Neoplasms
Dietary intake of walnut prevented Helicobacter pylori-associated gastric cancer through rejuvenation of chronic atrophic gastritis.
Neoplasms
Downregulation of 15-hydroxyprostaglandin dehydrogenase by interleukin-1? from activated macrophages leads to poor prognosis in pancreatic cancer.
Neoplasms
Effect of 15-hydroxyprostaglandin dehydrogenase gene on the proliferation of gastric cancer cell murine forestomach carcinoma.
Neoplasms
Effect of Lactobacillus rhamnosus GR-1 supernatant and fetal sex on lipopolysaccharide-induced cytokine and prostaglandin-regulating enzymes in human placental trophoblast cells: implications for treatment of bacterial vaginosis and prevention of preterm labor.
Neoplasms
Experimental cancer therapy using restoration of NAD+ -linked 15-hydroxyprostaglandin dehydrogenase expression.
Neoplasms
Expression of 15-hydroxyprostaglandin dehydrogenase and cyclooxygenase-2 in non-small cell lung cancer: Correlations with angiogenesis and prognosis.
Neoplasms
Expression of 15-hydroxyprostaglandin dehydrogenase, a COX-2 antagonist and tumour suppressor, is not altered in gastric carcinomas.
Neoplasms
Expression of prostaglandin- and vitamin D-metabolising enzymes in benign and malignant breast cells.
Neoplasms
Expression of vitamin D receptor (VDR), cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25(OH(2))D(3)) and prostaglandin E(2) (PGE(2)) serum level in ovarian cancer patients.
Neoplasms
Histone deacetylase inhibitors and transforming growth factor-beta induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells.
Neoplasms
Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer.
Neoplasms
Indomethacin, a COX inhibitor, enhances 15-PGDH and decreases human tumoral C cells proliferation.
Neoplasms
Indomethacin, a cox inhibitor, enhances 15-PGDH and decreases human tumoral C cells proliferation.
Neoplasms
Inhibition of 15-Hydroxyprostaglandin Dehydrogenase by Helicobacter pylori in Human Gastric Carcinogenesis.
Neoplasms
Inhibition of 15-PGDH causes Kras-driven tumor expansion through prostaglandin E2-ALDH1 signaling in the pancreas.
Neoplasms
Interleukin-10 modifies the effects of interleukin-1beta and tumor necrosis factor-alpha on the activity and expression of prostaglandin H synthase-2 and the NAD+-dependent 15-hydroxyprostaglandin dehydrogenase in cultured term human villous trophoblast and chorion trophoblast cells.
Neoplasms
Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression.
Neoplasms
Loss of 15-Hydroxyprostaglandin Dehydrogenase Increases Prostaglandin E2 in Pancreatic Tumors.
Neoplasms
Loss of 15-hydroxyprostaglandin dehydrogenase indicates a tumor suppressor role in pituitary adenomas.
Neoplasms
Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E2.
Neoplasms
MicroRNA-21 induces loss of 15-hydroxyprostaglandin dehydrogenase in early gastric tubular adenocarcinoma.
Neoplasms
miR-21 modulates prostaglandin signaling and promotes gastric tumorigenesis by targeting 15-PGDH.
Neoplasms
miR-21-mediated regulation of 15-hydroxyprostaglandin dehydrogenase in colon cancer.
Neoplasms
miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD).
Neoplasms
Montelukast, a CysLT1 receptor antagonist, reduces colon cancer stemness and tumor burden in a mouse xenograft model of human colon cancer.
Neoplasms
Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer.
Neoplasms
Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer.
Neoplasms
NAD(+)-Linked 15-Hydroxyprostaglandin Dehydrogenase: Structure and Biological Functions.
Neoplasms
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer.
Neoplasms
NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer.
Neoplasms
Non-canonical WNT5A signaling up-regulates the expression of the tumor suppressor 15-PGDH and induces differentiation of colon cancer cells.
Neoplasms
Nuclear Factor Erythroid 2-related Factor 2 Knockout Suppresses the Development of Aggressive Colorectal Cancer Formation Induced by Azoxymethane/Dextran Sulfate Sodium-Treatment in Female Mice.
Neoplasms
Oncolytic herpes simplex virus 1 encoding 15-prostaglandin dehydrogenase mitigates immune suppression and reduces ectopic primary and metastatic breast cancer in mice.
Neoplasms
Prognostic implication of 15-hydroxyprostaglandin dehydrogenase down-regulation in patients with colorectal cancer.
Neoplasms
Prostaglandin E2 Pathway Is Dysregulated in Gastric Adenocarcinoma in a Caucasian Population.
Neoplasms
Prostaglandin metabolizing enzymes in correlation with vitamin D receptor in benign and malignant breast cell lines.
Neoplasms
Reduction of 15-hydroxyprostaglandin dehydrogenase expression is an independent predictor of poor survival associated with enhanced cell proliferation in gastric adenocarcinoma.
Neoplasms
Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs).
Neoplasms
Regulation of 15-hydroxyprostaglandin dehydrogenase expression in hepatocellular carcinoma.
Neoplasms
Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression.
Neoplasms
ROS-Mediated 15-Hydroxyprostaglandin Dehydrogenase Degradation via Cysteine Oxidation Promotes NAD
Neoplasms
Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.
Neoplasms
Suppressed Helicobacter pylori-associated gastric tumorigenesis in Fat-1 transgenic mice producing endogenous ?-3 polyunsaturated fatty acids.
Neoplasms
Suppression of invasive properties of colorectal carcinoma SW480 cells by 15-hydroxyprostaglandin dehydrogenase gene.
Neoplasms
Synthetic triterpenoid induces 15-PGDH expression and suppresses inflammation-driven colon carcinogenesis.
Neoplasms
The effect of tumor necrosis factor ? (TNF?), interleukin 1? (IL1?) and interleukin 6 (IL6) on endometrial PGF2? synthesis, metabolism and release in early-pregnant pigs.
Neoplasms
The first case of primary hypertrophic osteoarthropathy with soft tissue giant tumors caused by HPGD loss-of-function mutation.
Neoplasms
Treatment of acromegaly by rosiglitazone via upregulating 15-PGDH in both pituitary adenoma and liver.
Neoplasms
Tumor growth inhibition by indomethacin in a mouse model of human medullary thyroid cancer: implication of cyclooxygenases and 15-hydroxyprostaglandin dehydrogenase.
Neoplasms
Tumour suppressor 15-hydroxyprostaglandin dehydrogenase induces differentiation in colon cancer via GLI1 inhibition.
Neoplasms
Upregulation of Prostaglandin E2 by Inducible Microsomal Prostaglandin E Synthase-1 in Colon Cancer.
Neoplasms, Multiple Primary
15-hydroxyprostaglandin dehydrogenase in colorectal mucosa as a potential biomarker for predicting colorectal neoplasms.
Obstetric Labor, Premature
15-hydroxyprostaglandin dehydrogenase and cyclooxygenase 2 messenger ribonucleic acid expression and immunohistochemical localization in human cervical tissue during term and preterm labor.
Obstetric Labor, Premature
15-hydroxyprostaglandin dehydrogenase: implications in preterm labor with and without ascending infection.
Obstetric Labor, Premature
Immunohistochemical localization, messenger ribonucleic acid abundance, and activity of 15-hydroxyprostaglandin dehydrogenase in placenta and fetal membranes during term and preterm labor.
Obstetric Labor, Premature
Preterm birth without progesterone withdrawal in 15-hydroxyprostaglandin dehydrogenase hypomorphic mice.
Obstetric Labor, Premature
Reduced Expression of Hydrogen Sulfide-Generating Enzymes Down-Regulates 15-Hydroxyprostaglandin Dehydrogenase in Chorion during Term and Preterm Labor.
Obstetric Labor, Premature
[Expression of cyclooxygenase-2 and 15-prostaglandin dehydrogenase of placenta and fetal membranes in patients of preterm labor]
Osteoarthropathy, Primary Hypertrophic
A novel homozygous splice site mutation in the HPGD gene causes mild primary hypertrophic osteoarthropathy.
Osteoarthropathy, Primary Hypertrophic
A novel recessive 15-hydroxyprostaglandin dehydrogenase mutation in a family with primary hypertrophic osteoarthropathy.
Osteoarthropathy, Primary Hypertrophic
Common and recurrent HPGD mutations in Caucasian individuals with primary hypertrophic osteoarthropathy.
Osteoarthropathy, Primary Hypertrophic
Complete form of pachydermoperiostosis: A case report.
Osteoarthropathy, Primary Hypertrophic
Establishment of a novel human iPSC line (SDQLCHi032-A) derived from a patient with primary hypertrophic osteoarthropathy caused by HPGD homozygous mutation.
Osteoarthropathy, Primary Hypertrophic
Homozygous mutations in the 15-hydroxyprostaglandin dehydrogenase gene in patients with primary hypertrophic osteoarthropathy.
Osteoarthropathy, Primary Hypertrophic
HPGD mutations cause cranioosteoarthropathy but not autosomal dominant digital clubbing.
Osteoarthropathy, Primary Hypertrophic
Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy.
Ovarian Neoplasms
Expression of vitamin D receptor (VDR), cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25(OH(2))D(3)) and prostaglandin E(2) (PGE(2)) serum level in ovarian cancer patients.
Pancreatic Neoplasms
Downregulation of 15-hydroxyprostaglandin dehydrogenase by interleukin-1? from activated macrophages leads to poor prognosis in pancreatic cancer.
Peptic Ulcer
15-PGDH inhibitors: the antiulcer effects of carbenoxolone, pioglitazone and verapamil in indomethacin induced peptic ulcer rats.
Pituitary Neoplasms
Loss of 15-hydroxyprostaglandin dehydrogenase indicates a tumor suppressor role in pituitary adenomas.
Pituitary Neoplasms
Treatment of acromegaly by rosiglitazone via upregulating 15-PGDH in both pituitary adenoma and liver.
Pre-Eclampsia
Decreased gene expression of 11beta-hydroxysteroid dehydrogenase type 2 and 15-hydroxyprostaglandin dehydrogenase in human placenta of patients with preeclampsia.
Pre-Eclampsia
In vitro activity of nicotinamide adenine dinucleotide- and nicotinamide adenine dinucleotide phosphate-linked 15-hydroxyprostaglandin dehydrogenases in placentas from normotensive and preeclamptic/eclamptic pregnancies.
Premature Birth
Preterm birth without progesterone withdrawal in 15-hydroxyprostaglandin dehydrogenase hypomorphic mice.
Premature Birth
Prostaglandin dehydrogenase is a target for successful induction of cervical ripening.
Premature Birth
[Spontaneous premature birth: physiopathology, predictors and management. The frequency is constant--early detection can improve therapeutic possibilities]
Prolactinoma
Loss of 15-hydroxyprostaglandin dehydrogenase indicates a tumor suppressor role in pituitary adenomas.
Prostatic Neoplasms
Induction of NAD(+)-linked 15-hydroxyprostaglandin dehydrogenase expression by androgens in human prostate cancer cells.
Prostatic Neoplasms
Synergistic induction of the nicotinamide adenine dinucleotide-linked 15-hydroxyprostaglandin dehydrogenase by an androgen and interleukin-6 or forskolin in human prostate cancer cells.
Pulmonary Fibrosis
Inhibiting eicosanoid degradation exerts antifibrotic effects in a pulmonary fibrosis mouse model and human tissue.
Sarcopenia
Inhibition of prostaglandin-degrading enzyme 15-PGDH rejuvenates aged muscle mass and strength.
Schistosomiasis
Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder.
Severe Combined Immunodeficiency
15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE2/PPAR?-mediated activation of p21(WAF1/Cip1.)
Skin Neoplasms
UV radiation inhibits 15-hydroxyprostaglandin dehydrogenase levels in human skin: evidence of transcriptional suppression.
Squamous Cell Carcinoma of Head and Neck
Apricoxib upregulates 15-PGDH and PGT in tobacco-related epithelial malignancies.
Stomach Neoplasms
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human gastric cancer.
Stomach Neoplasms
15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer.
Stomach Neoplasms
15-Hydroxyprostaglandin Dehydrogenase is Downregulated and Exhibits Tumor Suppressor Activity in Gastric Cancer.
Stomach Neoplasms
15-PGDH expression as a predictive factor response to neoadjuvant chemotherapy in advanced gastric cancer.
Stomach Neoplasms
15-PGDH Expression in Gastric Cancer: A Potential Role in Anti-Tumor Immunity.
Stomach Neoplasms
15-PGDH is reduced and induces apoptosis and cell cycle arrest in gastric carcinoma.
Stomach Neoplasms
Effect of 15-hydroxyprostaglandin dehydrogenase gene on the proliferation of gastric cancer cell murine forestomach carcinoma.
Stomach Neoplasms
Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression.
Stomach Neoplasms
MicroRNA-21 induces loss of 15-hydroxyprostaglandin dehydrogenase in early gastric tubular adenocarcinoma.
Stomach Neoplasms
Reduction of 15-hydroxyprostaglandin dehydrogenase expression is an independent predictor of poor survival associated with enhanced cell proliferation in gastric adenocarcinoma.
Tendinopathy
Increased 15-PGDH expression leads to dysregulated resolution responses in stromal cells from patients with chronic tendinopathy.
Thyroid Neoplasms
15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line.
Thyroid Neoplasms
Sequence of a novel mRNA coding for a C-terminal-truncated form of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase.
Thyroid Neoplasms
Tumor growth inhibition by indomethacin in a mouse model of human medullary thyroid cancer: implication of cyclooxygenases and 15-hydroxyprostaglandin dehydrogenase.
Triple Negative Breast Neoplasms
Upregulation of Cyclooxygenase-2/Prostaglandin E2 (COX-2/PGE2) Pathway Member Multiple Drug Resistance-Associated Protein 4 (MRP4) and Downregulation of Prostaglandin Transporter (PGT) and 15-Prostaglandin Dehydrogenase (15-PGDH) in Triple-Negative Breast Cancer.
Ureteral Obstruction
Deficiency in 15-hydroxyprostaglandin dehydrogenase activity after unilateral ureteral obstruction of the dog kidney.
Ureteral Obstruction
Increase in enzyme activities of prostaglandin biosynthesis and catabolism by acute ureteral ligation in rat kidney.
Ureteral Obstruction
Suppression of 15-hydroxyprostaglandin dehydrogenase messenger RNA concentration, protein expression, and enzymatic activity during human ureteral obstruction.
Urinary Bladder Neoplasms
Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder.
Urinary Bladder Neoplasms
Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression.
Urinary Bladder Neoplasms
Search for the tumor-related proteins of transition cell carcinoma in Taiwan by proteomic analysis.
Uterine Cervical Neoplasms
Down-regulation of HPGD by miR-146b-3p promotes cervical cancer cell proliferation, migration and anchorage-independent growth through activation of STAT3 and AKT pathways.
Uterine Hemorrhage
Mifepristone-induced vaginal bleeding is associated with increased immunostaining for cyclooxygenase-2 and decrease in prostaglandin dehydrogenase in luteal phase endometrium.
Uterine Inertia
Investigations on the potential role of prostaglandin E2 in canine uterine inertia.
Virus Diseases
Oncolytic herpes simplex virus 1 encoding 15-prostaglandin dehydrogenase mitigates immune suppression and reduces ectopic primary and metastatic breast cancer in mice.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
additional information
enzyme activity in the endometrium during the oestrous cycle and early pregnancy, overview
additional information
-
enzyme activity in the endometrium during the oestrous cycle and early pregnancy, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
the enzyme is expressed mainly in the glandular epithelium, enzyme activity during the oestrous cycle and early pregnancy, overview
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
recombinant His-tagged lung enzyme from Escherichia coli by nickel affinity chromatography
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
15-PGDH, DNA and amino acid sequence determination and analysis, functional overexpression of His-tagged lung enzyme in Escherichia coli
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Parent, M.; Madore, E.; MacLaren, L.A.; Fortier, M.A.
15-Hydroxyprostaglandin dehydrogenase in the bovine endometrium during the oestrous cycle and early pregnancy
Reproduction
131
573-582
2006
Bos taurus (Q309F3), Bos taurus
brenda
EXTERNAL LINKS (specific for EC-Number 1.1.1.141)
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
